BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 6883329)

  • 1. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
    Mulcahy RT; Siemann DW
    Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo interaction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice.
    Siemann DW; Maddison K; Wolf K; Hill SA; Keng PC
    Cancer Res; 1985 Jan; 45(1):198-202. PubMed ID: 3965132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
    Siemann DW; Morrissey S; Wolf K
    Cancer Res; 1983 Mar; 43(3):1010-3. PubMed ID: 6825075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-dose relationships for simultaneous misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea exposures in vitro.
    Mulcahy RT; Dembs N
    Cancer Res; 1983 Aug; 43(8):3539-43. PubMed ID: 6861127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW
    Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misonidazole-induced chemopotentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea toxicity in O6-methylguanine-DNA methyltransferase proficient (Mer+) and deficient (Mer-) cell lines.
    Mulcahy RT
    Cancer Res; 1986 Jun; 46(6):2892-7. PubMed ID: 3698015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced tumor responses through therapies combining CCNU, MISO and radiation.
    Siemann DW; Hill SA
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1623-6. PubMed ID: 6480451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
    Siemann DW
    Br J Cancer; 1981 Mar; 43(3):367-77. PubMed ID: 7225287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect in the KHT sarcoma of CCNU and MISO on cell cycle progression evaluated by flow-cytometry.
    Hill SA; Bauer KD; Keng PC; Siemann DW
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1619-22. PubMed ID: 6480450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.
    Workman P; Twentyman PR
    Br J Cancer; 1982 Aug; 46(2):249-59. PubMed ID: 7150475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut.
    Mulcahy RT; Siemann DW; Sutherland RM
    Br J Cancer; 1982 Jun; 45(6):835-42. PubMed ID: 6212075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.
    Wong KH; Wallen CA; Wheeler KT
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1043-50. PubMed ID: 2140824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased therapeutic benefit through the addition of misonidazole to a nitrosourea-radiation combination.
    Siemann DW; Hill SA
    Cancer Res; 1986 Feb; 46(2):629-32. PubMed ID: 3940631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in subpopulations of cells derived from solid KHT sarcomas by centrifugal elutriation following treatment with CCNU and MISO.
    Hill SA; Keng PC; Siemann DW
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1615-8. PubMed ID: 6480449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
    Hirst DG; Brown JM; Hazlehurst JL
    Cancer Res; 1983 May; 43(5):1961-5. PubMed ID: 6682009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of CCNU, MISO, and fractionated radiotherapy.
    Siemann DW; Alliet KL
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1379-82. PubMed ID: 3759559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.
    Mulcahy RT; Siemann DW; Sutherland RM
    Br J Cancer; 1981 Jan; 43(1):93-9. PubMed ID: 7459244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pretreatment with phenobarbital or SKF 525A on the toxicity and antitumor activity of lomustine.
    Siemann DW
    Cancer Treat Rep; 1983 Mar; 67(3):259-65. PubMed ID: 6831472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
    Siemann DW; Alliet K; Maddison K; Wolf K
    Cancer Treat Rep; 1985 Dec; 69(12):1409-14. PubMed ID: 3841024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.